Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Current status of 4-aminoquinoline resistance markers 18 years after cessation of chloroquine use for the treatment of uncomplicated falciparum malaria in the littoral coastline region of Cameroon.
Moyeh MN, Fankem SN, Ali IM, Sofeu D, Sandie SM, Njimoh DL, Ghogomu SM, Kimbi HK, Mbacham WF. Moyeh MN, et al. Among authors: ali im. Pathog Glob Health. 2022 Dec;116(8):509-514. doi: 10.1080/20477724.2022.2056674. Epub 2022 Mar 31. Pathog Glob Health. 2022. PMID: 35357271 Free PMC article.
Amodiaquine-Artesunate versus Artemether-Lumefantrine against Uncomplicated Malaria in Children Less Than 14 Years in Ngaoundere, North Cameroon: Efficacy, Safety, and Baseline Drug Resistant Mutations in pfcrt, pfmdr1, and pfdhfr Genes.
Ali IM, Netongo PM, Atogho-Tiedeu B, Ngongang EO, Ajua A, Achidi EA, Mbacham WF. Ali IM, et al. Malar Res Treat. 2013;2013:234683. doi: 10.1155/2013/234683. Epub 2013 Dec 15. Malar Res Treat. 2013. PMID: 24455414 Free PMC article. Retracted.
Host candidate gene polymorphisms and associated clearance of P. falciparum amodiaquine and fansidar resistance mutants in children less than 5 years in Cameroon.
Ali IM, Evehe MS, Netongo PM, Atogho-Tiedeu B, Akindeh-Nji M, Ngora H, Domkam IK, Diakite M, Baldip K, Ranford-Cartwright L, Mimche PN, Lamb T, Mbacham WF. Ali IM, et al. Pathog Glob Health. 2014 Oct;108(7):323-33. doi: 10.1179/2047773214Y.0000000159. Epub 2014 Nov 12. Pathog Glob Health. 2014. PMID: 25388906 Free PMC article. Clinical Trial.
Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children.
Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, Ndikum VN, Evehe MS, Froeschl G, Heumann C, Mansmann U, Ogundahunsi O, Mbacham WF. Nji AM, et al. Among authors: ali im. Malar J. 2015 Jan 28;14:27. doi: 10.1186/s12936-014-0521-2. Malar J. 2015. PMID: 25626448 Free PMC article. Clinical Trial.
Effects of Drug Policy Changes on Evolution of Molecular Markers of Plasmodium falciparum Resistance to Chloroquine, Amodiaquine, and Sulphadoxine-Pyrimethamine in the South West Region of Cameroon.
Moyeh MN, Njimoh DL, Evehe MS, Ali IM, Nji AM, Nkafu DN, Masumbe PN, Barbara AT, Ndikum VN, Mbacham WF. Moyeh MN, et al. Among authors: ali im. Malar Res Treat. 2018 May 2;2018:7071383. doi: 10.1155/2018/7071383. eCollection 2018. Malar Res Treat. 2018. PMID: 29854394 Free PMC article.
Drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon: a systematic review and meta-analysis (1998-2020).
Niba PTN, Nji AM, Evehe MS, Ali IM, Netongo PM, Ngwafor R, Moyeh MN, Ngum LN, Ndum OE, Acho FA, Mbu'u CM, Fosah DA, Atogho-Tiedeu B, Achonduh-Atijegbe O, Djokam-Dadjeu R, Chedjou JPK, Bigoga JD, Moukoko CEE, Ajua A, Achidi E, Tallah E, Leke RGF, Tourgordi A, Ringwald P, Alifrangis M, Mbacham WF. Niba PTN, et al. Among authors: ali im. Malar J. 2021 Jan 9;20(1):32. doi: 10.1186/s12936-020-03543-8. Malar J. 2021. PMID: 33422080 Free PMC article.
119 results